Find clinical trials for Alzheimer's Disease in New York, NY
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Alzheimer's Disease trials near New York, NY, USA:
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...
Brooklyn, New York, United States of America and 67 other locations
designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...
Phase 2
New York, New York, United States and 45 other locations
the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's...
New York, New York, United States and 9 other locations
reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's...
Phase 3
Springfield, New Jersey, United States and 75 other locations
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...
Phase 2, Phase 3
Bronx, New York, United States and 116 other locations
is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...
Phase 3
New York, New York, United States and 109 other locations
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...
Phase 2
Springfield, New Jersey, United States and 69 other locations
-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.Part A consists of a Screening Period (up t...
Phase 1
Brooklyn, New York, United States and 23 other locations
versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...
Phase 2
Stamford, Connecticut, United States and 102 other locations
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive...
Phase 2
Staten Island, New York, United States and 34 other locations
Clinical trials
Research sites
Resources
Legal